Robert Dreicer, MD, MS, MACP, FASCO | Authors


A 65-Year-Old Female With Urothelial Carcinoma

September 14, 2020

Dr Robert Dreicer reviews a case of advanced urothelial cancer and explains the patient’s eligibility for platinum-based chemotherapy followed by maintenance therapy with a checkpoint inhibitor.

Expert Discusses the Role of PD-L1 Expression as a Predictive Biomarker in Urothelial Carcinoma

September 20, 2019

Robert Dreicer, MD, discusses the role of biomarkers to predict response to immunotherapy in patients with urothelial carcinoma. He highlights the current status of using PD-L1 expression as a predictive biomarker to immunotherapy.